Influenza A Complications in Immunocompromised and High-Risk Populations

The 2024–25 influenza season broke records for severity, so you can set aside any lingering sense that flu season is routine or predictable. CDC's Influenza Hospitalization Surveillance Network (FluSurv-NET) recorded a cumulative influenza-associated hospitalization rate of 127.1 per 100,000 population for the period running October 1, 2024, through April 30, 2025. That rate surpassed every end-of-season figure going back to the 2010–11 season. Two influenza A subtypes, A(H1N1)pdm09 and A(H3N2), circulated at the same time, and H3N2 in particular has a long track record of hitting older adults and immunocompromised patients harder than other strains do.

A single population-level number like 127.1 per 100,000 hides more than it reveals. Averaged across an entire country, it flattens out the fact that risk is not spread evenly: some patients walk through this season with a few days of fever, while others, facing the same virus, end up in the ICU or die. The populations that absorb the worst of that gap are the ones whose immune systems meet the virus on different terms from the start, and specific disruptions in innate and adaptive immunity explain why.

The biology behind how immunocompromised individuals experience influenza differently

Calling immunocompromised patients "weaker" misses the actual mechanism: specific components of the immune system are disrupted, and the clinical consequences are more severe than that label suggests. What changes is more specific: certain components of the innate and adaptive immune response, the systems responsible for detecting the virus early and then mounting a targeted response against it, are disrupted in ways that alter how the infection behaves inside the body from the first exposure onward.

In solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, this disruption carries a measurable cost: it is independently associated with a 3.2-fold increase in ICU admission. The downstream effects compound from there. Viral shedding runs longer than it would in a healthy adult. The infectious period stretches out, and the virus keeps replicating inside the host well past the point where a normal immune system would have cleared it. That extended window raises the odds of bacterial and fungal superinfections taking hold on top of the flu itself, and in transplant patients it can trigger organ rejection episodes, a complication with no equivalent in the general population. Mortality rises accordingly.

What makes this especially dangerous from a clinical standpoint is a kind of diagnostic paradox. Severely immunocompromised patients often have fewer early symptoms, not more, even as their risk of a severe outcome climbs. A blunted immune response means a blunted fever, a blunted cough, a blunted set of the warning signs clinicians normally rely on to catch influenza early. The window for identifying and treating the infection before it progresses is narrower and harder to see in exactly the patients who need early treatment the most.

This chain, suppressed immune function leading to blunted early symptoms, leading to delayed recognition, leading to prolonged viral activity, leading to severe downstream complications, holds across the immunocompromised spectrum. Transplant recipients, patients on chemotherapy, people on B-cell-depleting therapies, and people with advanced HIV all sit somewhere along this same basic pathway, even though the specific immune deficit driving it differs by underlying condition and treatment. That shared mechanism is what turns the severity statistics in the next section from abstract numbers into the predictable consequence of a single biological process.

How severity scales across the distinct high-risk populations

Immunocompromised and other high-risk patients do not share one uniform risk profile. Each group carries a distinct pattern of vulnerability, shaped by how that group's physiological state interacts with the virus, so clinicians treating one population need a different mental map than those treating another.

Among transplant recipients, the numbers are stark. Research from CHU de Nantes on critically ill immunocompromised patients found ICU mortality among immunocompromised subjects running at roughly three times the rate seen in non-immunocompromised patients hospitalized for influenza pneumonia. A separate study looked at immunocompromised adults hospitalized with influenza-related pneumonia and found that this status was independently tied to a marked increase in both 30-day mortality and ICU admission. Solid organ transplant recipients show a similar, somewhat less extreme pattern, but with a complication unique to that group: the combination of ongoing immunosuppressive therapy and an allograft's vulnerability to rejection adds a layer of risk that patients with chemotherapy-induced or HIV-related immunosuppression simply do not carry.

Among people living with HIV, risk tracks closely with how well the underlying infection is controlled, and that distinction matters enough that it should never be collapsed into a single category. Patients with a very low CD4 count, or those not on antiretroviral therapy, face the highest risk of serious influenza complications and the most prolonged viral shedding. If HIV is well-controlled on effective antiretroviral therapy, the patient sits in a meaningfully lower-risk position. Treating every person with an HIV diagnosis as equally vulnerable to severe influenza outcomes would misstate the actual clinical picture.

Older adults show a pattern that runs almost opposite to what you would expect. Infection incidence in this age group is actually the lowest of any adult population measured, yet older adults absorb the largest share of hospitalizations and deaths from influenza. That gap is a function of severity per infection rather than frequency of infection: when an older adult does contract the flu, the odds of a severe outcome are substantially higher than for a younger adult with the same exposure. Complications in this group also extend beyond the respiratory system in a way that surprises many clinicians outside specialist practice. Influenza is increasingly recognized as a trigger for acute cardiovascular events in older adults, including myocardial infarction, heart failure, and stroke, so the clinical risk calculus for an older patient with flu has to account for organs well outside the lungs.

Pregnancy is its own distinct risk state. Studies published between 2020 and 2025 tie maternal influenza infection to a higher risk of spontaneous abortion, preterm birth, and congenital malformations, and infection in the first trimester specifically raises the risk of neural tube defects and congenital heart defects. A 2025 study found increased odds of hospitalization among pregnant women with influenza, reinforcing that pregnancy itself constitutes a measurably elevated vulnerability to severe respiratory viral disease, independent of any other underlying condition.

Children with a pre-existing neurological condition face a risk pattern that centers on a different kind of complication. In this cohort, a pre-existing neurological condition stood out as the strongest independent predictor of neurological complications from influenza, so clinicians treating these children should watch closely even when respiratory symptoms look mild.

Morbid obesity, defined as a BMI above 40, rounds out the list, but it gets far less attention than it actually warrants. Patients in this category face a higher risk of severe outcomes, both hospitalization and death, compared with patients who have obesity alone or a normal body weight. This risk factor gets so little airtime next to transplant status or age, and that says something about how uneven public and clinical awareness of influenza risk really is.

A complication specific to immunocompromised hosts: antiviral resistance emerging during treatment

Severity alone does not capture the full danger facing immunocompromised patients during an influenza infection. The standard antiviral response, the very treatment meant to rescue these patients, carries a failure mode in this population that broader flu literature rarely foregrounds: the conditions that make antivirals most necessary are the same conditions that make resistance most likely to develop.

The mechanism follows directly from what prolonged viral shedding does inside an immunocompromised host. High viral loads and extended shedding mean these patients need antiviral treatment more urgently than most. Those same conditions, sustained viral replication under the selective pressure of a single drug, create close to ideal circumstances for resistance mutations to emerge during the course of treatment itself.

A documented case shows how fast this can happen. An HSCT recipient infected with influenza A/H3N2 developed the oseltamivir resistance mutation R292K within 12 days of starting treatment, accompanied by a dramatic rise in the drug's IC50, the concentration needed to inhibit the virus. Oseltamivir had been functionally inactivated in under two weeks of monotherapy, resistance emerging not after months of imperfect adherence or repeated courses but within less than two weeks of a single standard treatment regimen for a drug class clinicians often treat as a reliable default.

The low genetic barrier to oseltamivir resistance in influenza A is a predictable outcome of prolonged monotherapy in a host whose immune system cannot clear the virus on its own timeline, a structural vulnerability built into the standard treatment approach for exactly the patients who rely on that approach most. The clinical response has to follow from that reality. Virologic monitoring of immunocompromised patients during antiviral treatment is warranted so that resistance can be caught while it is still developing rather than after the drug has already stopped working; whether single-drug oseltamivir therapy is even adequate in HSCT recipients specifically remains an open clinical question.

Vaccination as the primary protective strategy despite attenuated responses

Vaccination still stands as the most important protective tool for high-risk populations, even though it works less well in immunocompromised individuals than in healthy adults. A reduced immune response to a vaccine is not the same thing as a useless one, and treating a partial benefit as no benefit leads to false reassurance and to patients skipping other precautions they still need. The 2025 IDSA guidelines on influenza vaccination for immunocompromised patients strongly recommend that all immunocompromised individuals aged 6 months and older get an age-appropriate 2025-2026 influenza vaccine, and they acknowledge directly that evidence in this population shows a reduction in influenza-associated hospitalization that is meaningful but modest.

Which formulation a patient receives changes the degree of protection on offer, and the choice matters most for older adults. The Medical Letter's review of the 2025-2026 influenza vaccines (Issue 1738) notes that ACIP preferentially recommends adults aged 65 and older receive a high-dose vaccine (Fluzone High-Dose), an adjuvanted vaccine (Fluad), or a recombinant vaccine (Flublok) over a standard-dose option. A 2024 analysis found that high-dose formulations reached a relative vaccine effectiveness of up to 8.4% in preventing cardiorespiratory hospitalization in adults 65 and older, a modest but real margin on top of standard protection. One formulation is ruled out for this population: live attenuated influenza vaccine, sold as FluMist, must not be given to immunocompromised persons, a restriction the AAP's 2025-2026 policy statement and guideline summary lays out because the live virus itself poses a risk this population cannot safely absorb.

Timing matters nearly as much as which vaccine you choose, especially around immunosuppressive treatment schedules. If a child is starting anti-B-cell therapies such as rituximab or alemtuzumab, they should ideally get an inactivated or recombinant vaccine two to four weeks before starting that therapy, and once the therapy begins, inactivated vaccine should wait six months after the last dose, ideally until B-cell recovery can be documented. HCT recipients can begin inactivated vaccination four to six months after transplant, while SOT recipients can start at three months post-transplant, or as early as one month during an active flu season when the exposure risk outweighs waiting. Children with malignant neoplasms on chemotherapy should get an inactivated or recombinant vaccine at least two weeks before cytotoxic chemotherapy whenever that scheduling is clinically possible. If a patient has received a targeted CAR-T cell therapy and is in remission, not needing further chemotherapy or HCT, they should wait at least six months after infusion before a non-live vaccine is considered.

Humoral responses run lowest precisely in patients on B-cell-active therapies like rituximab and mycophenolate, so the patients who benefit least from a given dose of vaccine are often the same patients where timing and post-vaccination immune monitoring matter most. So what protective option remains for these hardest-to-protect patients beyond their own vaccine response? Vaccinating the household contacts of immunocompromised individuals offers a direct answer: it lowers the probability that the virus ever reaches the immunocompromised person at all, shifting part of the protective burden onto the people surrounding them rather than relying solely on an immune system that may not respond fully on its own.